Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present.

Date publication

janvier 2022

Journal

Expert opinion on therapeutic patents

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen

Tous les auteurs :
Hu S, Hui Z, Duan J, Garrido C, Xie T, Ye XY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35001778

Résumé

Ataxia telangiectasia and RAD3-related kinase (ATR) is one of the key PIKKs family members important for DNA damage response and repair pathways. Targeting ATR kinase for potential cancer therapy has attracted a great deal of attention to both pharmaceutical industries and academic community.

Mots clés

DNA damage response (DDR), ataxia telangiectasia and RAD3-related kinase (ATR), cancer therapy, inhibitor, patent review

Référence

Expert Opin Ther Pat. 2022 Jan 10;: